21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Liver-primed CD8 + T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The liver is a tolerogenic environment exploited by persistent infections, such as hepatitis B (HBV) and C (HCV) viruses. In a murine model of intravenous hepatotropic adenovirus infection, liver-primed antiviral CD8 + T cells fail to produce proinflammatory cytokines and do not display cytolytic activity characteristic of effector CD8 + T cells generated by infection at an extrahepatic, that is, subcutaneous, site. Importantly, liver-generated CD8 + T cells also appear to have a T-regulatory (T reg) cell function exemplified by their ability to limit proliferation of antigen-specific T-effector (T eff) cells in vitro and in vivo via T-cell immunoglobulin and mucin 3 (Tim-3) expressed by the CD8 + T reg cells. Regulatory activity did not require recognition of the canonical Tim-3 ligand, galectin-9, but was dependent on CD8 + T reg cell-surface Tim-3 binding to the alarmin, high-mobility group box 1 (HMGB-1). Conclusion: Virus-specific Tim-3 +CD8 + T cells operating through HMGB-1 recognition in the setting of acute and chronic viral infections of the liver may act to dampen hepatic T-cell responses in the liver microenvironment and, as a consequence, limit immune-mediated tissue injury or promote the establishment of persistent infections. (H epatology 2014;59:1351-1365)

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.

          The mechanisms by which tumor microenvironments modulate nucleic acid-mediated innate immunity remain unknown. Here we identify the receptor TIM-3 as key in circumventing the stimulatory effects of nucleic acids in tumor immunity. Tumor-associated dendritic cells (DCs) in mouse tumors and patients with cancer had high expression of TIM-3. DC-derived TIM-3 suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism. In contrast, TIM-3 interacted with the alarmin HMGB1 to interfere with the recruitment of nucleic acids into DC endosomes and attenuated the therapeutic efficacy of DNA vaccination and chemotherapy by diminishing the immunogenicity of nucleic acids released from dying tumor cells. Our findings define a mechanism whereby tumor microenvironments suppress antitumor immunity mediated by nucleic acids.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulatory T cells: friend or foe in immunity to infection?

            Homeostasis in the immune system depends on a balance between the responses that control infection and tumour growth and the reciprocal responses that prevent inflammation and autoimmune diseases. It is now recognized that regulatory T cells have a crucial role in suppressing immune responses to self-antigens and in preventing autoimmune diseases. Evidence is also emerging that regulatory T cells control immune responses to bacteria, viruses, parasites and fungi. This article explores the possibility that regulatory T cells can be both beneficial to the host, through limiting the immunopathology associated with anti-pathogen immune responses, and beneficial to the pathogen, through subversion of the protective immune responses of the host.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

              CD4+CD25+ regulatory T cells (Treg) have been shown to maintain immune tolerance against self and foreign Ags, but their role in persistent viral infection has not been well-defined. In this study, we investigated whether and where CD4+CD25+ Treg contribute to the development of chronic hepatitis B (CHB). One hundred twenty-one patients were enrolled, including 16 patients with acute hepatitis B, 76 with CHB, and 29 with chronic severe hepatitis B. We demonstrated that in chronic severe hepatitis B patients, the frequencies of CD4+CD25+ Treg in both PBMC and liver-infiltrating lymphocytes were significantly increased and there was a dramatic increase of FoxP3(+)-cell and inflammatory cell infiltration in the liver compared with healthy controls. In CHB patients, circulating CD4+CD25+ Treg frequency significantly correlates with serum viral load. In acute hepatitis B patients, circulating CD4+CD25+ Treg frequency was initially low and with time, the profile reversed to exhibit an increased number of circulating Treg in the convalescent phase and restored to normal levels upon resolution. In PBMC taken from infected patients, depletion of CD4+CD25+ Treg led to an increase of IFN-gamma production by HBV-Ag-stimulated PBMC. In addition, CD4+CD25+ Treg were capable of suppressing proliferation of autologous PBMC mediated by HBV Ags, which probably reflects the generation of HBV-Ag-specific Treg in circulation and in the liver of HBV-infected patients. Together, our findings suggest that CD4+CD25+ Treg play an active role not only in modulating effectors of immune response to HBV infection, but also in influencing the disease prognosis in patients with hepatitis B.
                Bookmark

                Author and article information

                Journal
                Hepatology
                Hepatology
                hep
                Hepatology (Baltimore, Md.)
                BlackWell Publishing Ltd (Oxford, UK )
                0270-9139
                1527-3350
                April 2014
                28 February 2014
                : 59
                : 4
                : 1351-1365
                Affiliations
                [1 ]Department of Microbiology, Immunology, and Cancer Biology, Beirne B. Carter Center for Immunology Research, University of Virginia Charlottesville, VA
                [2 ]Department of Pathology, University of Virginia Charlottesville, VA
                Author notes
                Address reprint requests to: Young S. Hahn, Ph.D., Beirne B. Carter Center for Immunology Research, University of Virginia, P.O. Box 801386, Charlottesville, VA 22908. E-mail: ysh5e@ 123456virginia.edu ; fax: 434-924-1221.

                The National Institutes of Health (grants DK063222 and U19 AI083024) and the Immunology Training Fellowship (T32 AI07496) supported this publication.

                View this article online at wileyonlinelibrary.com.

                Potential conflict of interest: Nothing to report.

                Article
                10.1002/hep.26938
                3970181
                24677194
                de4a1266-996d-4c61-8d78-556733d2c52a
                © 2014 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases

                This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 02 August 2013
                : 12 November 2013
                Categories
                Viral Hepatitis

                Gastroenterology & Hepatology
                Gastroenterology & Hepatology

                Comments

                Comment on this article